A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

* Participants must be diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer * Participants must have folate receptor alpha positive tumor expression as defined in the protocol * Participants must have platinum-resistant ovarian cancer, defined as progression within 6 months from completion of a minimum of four cycles of platinum-containing therapy. * Participants must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy is appropriate as the next line of treatment * Participants must have at least one lesion that meets the definition of measurable disease by RECIST 1.1

* Diagnosis of clear cell, low grade ovarian cancer or mixed tumors * Participants with primary platinum-refractory disease * Serious concurrent illness or clinically relevant active infection as defined in the protocol * Prior treatment with mirvetuximab soravtansine * Women who are pregnant or breast feeding